PER-091-09已完成未知
ASER ASSISTED IMMUNOTHERAPY
IMMUNOPHOTONICS / THE SOURCE SAC,0 个研究点目标入组 10 人开始时间: 2009年9月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 至 80（—）
- 性别
- Female
入选标准
- •Be over 20 years old and under 80.
- •Have clinical cycles of recurrent breast cancer
- •Have no other therapeutic options at hand.
- •Be considered able to return for all study visits for one year
排除标准
- •Have another systemic disease that compromises the tumor being studied.
- •Be receiving or having received in a period of 4 weeks before the start of the study treatment any new drug under investigation: cytokine or systemic steroid therapy.
- •Be allergic to shellfish
- •Have cardiovascular disease of class III or IV according to the functional criteria of the association of cardiac studies in New York.
- •Currently, have samples of the history of liver disease, kidney disease, allergic rheumatology (i.e. anaphylactic reaction) or CMS (including seizures)
- •Have Diabetes Melitus.
- •Have signs or history of clinical depression or suicidal tendencies.
- •Have autoimmune thyroid disease or Systemic Lupus Erythematosus
- •Having skin of type 5 or 6 in the area to be treated (laser light cannot penetrate skin that is very dark enough).
- •Have a tattoo that covers the area to be treated (the laser light cannot penetrate the tattoos well enough).
研究者
相似试验
已完成
2 期
1E10 anti-idiotype vaccine, metastatic colon, phase II.Colon adenocarcinoma phase IV or evolvable metastatic diseaseColonic NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesColorectal NeoplasmsRPCEC00000006Center of Molecular Immunology (CIM)40
已完成
2 期
1E10 anti-idiotype vaccine, metastatic breast cancer, phase IIBreast carcinoma in stage IV or progressive metastatic diseaseBreast NeoplasmsCarcinomaBreast DiseasesRPCEC00000008Center of Molecular Immunology (CIM)80
招募中
不适用
MOODSTRATIFICATION IMMUNOSTRATAPremature immune ageing to predict the effect of physical training intervention, in mood disordersF32F33F31Depressive episodeRecurrent depressive disorderBipolar affective disorderDRKS00022887niversitätsklinikum Münster500
撤回
不适用
MOODSTRATIFICATION Immune Signatures for Therapy Stratification in Major Mood Disordersauto - immune diseasesmood disorders100038161000225210027946NL-OMON48608niversitair Medisch Centrum Groningen90
进行中（未招募）
1 期
Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)Myasthenia Gravis Systemic Lupus ErythematosusRheumatoid ArthritisEUCTR2013-005362-19-DECharité - Universitätsmedizin Berlin18